By admin 
The Health Resources and Services Administration (HRSA), the federal agency tasked with oversight of the nation’s healthcare safety net, has released a staggering new report revealing that prescription medicines purchased through the 340B Drug Discount Program reached a record $100 billion in 2025. This milestone represents a 22.8% increase from the previous year, a growth rate that far outpaces general inflation and total national drug spending trends. The data underscores the program’s massive expansion from a niche provision for safety-net providers into a primary pillar of the American pharmaceutical economy, setting the stage for a renewed and vitriolic battle between the pharmaceutical industry, hospital systems, and federal regulators.
According to the HRSA update, high-cost specialty medicines are the primary engine driving this fiscal surge. These "expensive medicines" accounted for $61.9 billion, or nearly 62% of all purchases within the program. Leading the pack was Merck’s blockbuster immunotherapy treatment, Keytruda, which saw nearly $8.9 billion in 340B spending. Close behind was Gilead Sciences’ HIV treatment, Biktarvy, which accounted for more than $4.47 billion. The concentration of spending on these high-margin biologics and chronic disease treatments highlights how the 340B program has become intrinsically linked to the most profitable sectors of the pharmaceutical market, particularly oncology and infectious disease.
The 340B program, established by Congress in 1992 under Section 340B of the Public Health Service Act, was originally designed to help "covered entities"—hospitals and clinics serving high volumes of low-income or uninsured patients—"stretch scarce Federal resources as far as possible." By requiring drug manufacturers to provide outpatient drugs at significantly discounted prices (typically 25% to 50% below the Average Manufacturer Price), the law intended for these savings to be reinvested into comprehensive patient services. However, as the 2025 data suggests, the program has grown into a $100 billion behemoth, leading critics to question whether the original intent of the law is still being met or if it has morphed into a profit-generating engine for large hospital systems.
The 22.8% year-over-year growth is attributed to several converging factors. First is the sheer expansion of "covered entities." Over the last decade, the number of hospital sites and associated clinics eligible for 340B discounts has ballooned. This is partly due to the Affordable Care Act’s expansion of eligibility and partly due to the aggressive acquisition of independent physician practices by large 340B-eligible hospital systems. When a hospital system acquires a private oncology clinic, that clinic often becomes eligible for 340B discounts, allowing the hospital to purchase drugs like Keytruda at a steep discount while billing insurers at much higher rates.
Second, the role of contract pharmacies has radically altered the landscape. Since a 2010 HRSA guidance allowed covered entities to use an unlimited number of outside retail pharmacies to dispense 340B-discounted drugs, the program’s reach has exploded. This has created a complex web of "middlemen," including pharmacy benefit managers (PBMs) and third-party administrators, who all take a slice of the 340B margin. In 2025, the friction between drugmakers and these contract pharmacies reached a boiling point, with many manufacturers continuing to restrict discounts to these outside entities, leading to a flurry of litigation that has reached the highest levels of the federal court system.
The pharmaceutical industry, represented by trade groups like PhRMA, has used the $100 billion figure to argue for urgent legislative reform. "The 340B program is no longer a safety net; it is a black hole of accountability," said one industry analyst following the release of the HRSA data. Drugmakers argue that because there is no federal requirement for hospitals to pass 340B savings directly to patients or even to report how the savings are used, the program effectively subsidizes hospital bottom lines rather than reducing patient out-of-pocket costs. They point to the $8.9 billion spent on Keytruda as evidence that the program is being leveraged in the highest-cost therapeutic areas to maximize the "spread" between the discounted purchase price and the insurance reimbursement.
Conversely, hospital advocates, including the group 340B Health, argue that the $100 billion figure is a sign of the program’s success, not its failure. They contend that the growth reflects the rising cost of drugs and the increasing number of patients who rely on safety-net providers for life-saving care. For many rural hospitals and federally qualified health centers (FQHCs), 340B savings are the difference between staying open and shuttering their doors. These providers use the funds to provide free medications to the uninsured, fund mobile health clinics, staff specialized HIV/AIDS units, and offer transportation services for patients in "medical deserts."
"Without 340B, the American healthcare safety net would collapse under the weight of skyrocketing drug prices," a spokesperson for a major public hospital system noted. "The increase in spending on drugs like Biktarvy reflects our commitment to treating HIV in vulnerable populations where the alternative is often no treatment at all. The pharmaceutical industry is focusing on the $100 billion top-line number to distract from the fact that they are the ones setting the high list prices in the first place."
The HRSA data also sheds light on the specific therapeutic areas that are dominating the 340B landscape. Oncology remains the largest sector, driven by the shift toward outpatient infusion centers and the introduction of high-cost immunotherapies. Beyond Keytruda, other PD-1 and PD-L1 inhibitors have seen double-digit growth in 340B volume. The HIV market is also a significant contributor, with Biktarvy and other antiretroviral therapies seeing high utilization. The rise of "orphan drugs"—those designed for rare diseases—has also added to the 340B total, as many of these medications carry price tags in the hundreds of thousands of dollars per year.
The lack of transparency in the program remains the central point of contention. Currently, covered entities are not required to report their "net 340B income" or detail the specific programs funded by those savings. This lack of data has made it difficult for policymakers to determine the true impact of the program on patient outcomes. In response, several bipartisan bills were introduced in Congress throughout 2025 and into 2026, aiming to mandate more rigorous reporting requirements. These proposals, such as the SUSTAIN 340B Act, seek to create a standardized "transparency report" that would track 340B savings from the point of purchase to the point of patient care.
However, the political climate remains deeply divided. While some lawmakers are concerned about hospital transparency, others are focused on the "bad behavior" of drug manufacturers who have unilaterally restricted discounts. The 2025 spending data is likely to be used as a weapon by both sides in upcoming congressional hearings. Manufacturers will point to the $100 billion as a sign of a "runaway program," while hospitals will point to it as evidence of the "crushing burden of drug costs" that 340B helps them manage.
The role of the HRSA itself has also come under scrutiny. While the agency oversees the program, its regulatory authority has been limited by court rulings that have restricted its ability to issue binding rules on certain aspects of 340B, such as contract pharmacy restrictions. The 2025 report serves as a call to action for HRSA to take a more assertive role in auditing both covered entities and manufacturers to ensure compliance with the existing statute.
Looking ahead to the remainder of 2026, the 340B program is expected to continue its upward trajectory. The introduction of new gene therapies and increasingly sophisticated biologics—many of which will be administered in 340B-eligible outpatient settings—suggests that the $100 billion mark is not a ceiling, but a new baseline. As the debate over U.S. drug pricing continues to dominate the national discourse, the 340B program will remain at the center of the storm, representing either a vital lifeline for the poor or a cautionary tale of unintended consequences in federal healthcare policy.
Ultimately, the HRSA data confirms what many in the industry have suspected for years: 340B is no longer a minor discount program; it is a fundamental component of how healthcare is financed in the United States. With $100 billion at stake, the fight over who controls those dollars—and who truly benefits from them—is only just beginning. As Ed Silverman has noted in his Pharmalot columns, the tension between affordability, access, and corporate profit is nowhere more visible than in the rapid, unrelenting growth of the 340B Drug Discount Program. The coming year will likely determine whether the program can be reformed to satisfy its critics without dismantling the essential services it provides to millions of America’s most vulnerable patients.
